Compare ITRG & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRG | ASMB |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.9M | 512.1M |
| IPO Year | 2017 | 2010 |
| Metric | ITRG | ASMB |
|---|---|---|
| Price | $2.24 | $20.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $5.75 | ★ $51.20 |
| AVG Volume (30 Days) | ★ 1.5M | 190.9K |
| Earning Date | 11-11-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.41 | N/A |
| Revenue Next Year | $26.85 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $19.25 |
| 52 Week High | $4.87 | $39.71 |
| Indicator | ITRG | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 44.99 |
| Support Level | $2.00 | $19.30 |
| Resistance Level | $2.30 | $21.65 |
| Average True Range (ATR) | 0.11 | 1.03 |
| MACD | 0.00 | 0.29 |
| Stochastic Oscillator | 46.27 | 60.07 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.